Phase II Study of Bevacizumab and Vorinostat for Patients with Recurrent World Health Organization Grade 4 Malignant Glioma

LESSONS LEARNED. Combination regimen with bevacizumab (BEV) and vorinostat is well tolerated in patients with recurrent glioblastoma. Treatment of recurrent glioblastoma remains challenging as this study and others attempt to improve progression‐free survival and overall survival with BEV‐containing...

पूर्ण विवरण

में बचाया:
ग्रंथसूची विवरण
में प्रकाशित:Oncologist
मुख्य लेखकों: Ghiaseddin, Ashley, Reardon, David, Massey, Woody, Mannerino, Alex, Lipp, Eric S., Herndon, James E., McSherry, Frances, Desjardins, Annick, Randazzo, Dina, Friedman, Henry S., Peters, Katherine B.
स्वरूप: Artigo
भाषा:Inglês
प्रकाशित: AlphaMed Press 2017
विषय:
Clinical Trial Results
ऑनलाइन पहुंच:https://ncbi.nlm.nih.gov/pmc/articles/PMC5813746/
https://ncbi.nlm.nih.gov/pubmed/29133513
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2017-0501
टैग : टैग जोड़ें
कोई टैग नहीं, इस रिकॉर्ड को टैग करने वाले पहले व्यक्ति बनें!

समान संसाधन